US expert reports highlights the benefits of levofloxacin in the treatment of community-acquired pneumonia

A recent review published by staff in the Department of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, Virginia, USA, describes in detail the many benefits of levofloxacin as a treatment for community-acquired pneumonia (CAP). The safety and efficacy of 500 mg levofloxacin, once daily for 10 days, is well established and high-dose (750 mg) short-course (5 days) once-daily levofloxacin has now been approved in the US for the treatment of CAP. The high-dose, short-course treatment maximizes its concentration-dependent action, reduces the potential for drug resistance and increases patient compliance.

Expert Rev Anti Infect Ther. 2010 May;8(5):505-14.

Source : http://www.ncbi.nlm.nih.gov/pubmed/20455679?dopt=Abstract